Tirzepatide
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
National Cancer Institute (NCI)protein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PEG LOXENATIDE Fudan University | Phase 2/3 | B |
Letrozole Xiaojun Chen | Phase 2/3 | B |
Liraglutide Xiaojun Chen | Phase 2/3 | B |
Metformin Xiaojun Chen | Phase 2/3 | B |
MEGESTROL ACETATE IMPURITY B Xiaojun Chen | Phase 2/3 | B |
Levonorgestrel Xiaojun Chen | Phase 2/3 | B |
Same molecule, other indications
Tirzepatide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →